Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD
11 10월 2023 - 9:35PM
Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a
developmental stage biopharmaceutical company focused on merging
traditional therapeutics with psychedelic research, today announced
plans to initiate a human factor study of its targeted prophylactic
treatment SPC-15 for the treatment of post-traumatic stress
disorder (PTSD). The study will evaluate the human factor interface
and usability of SPC-15’s intranasal formulation in combination
with a nose-to-brain delivery mechanism.
“The human factors study is an important step as we prepare and
plan to enter the clinic with SPC-15 for the treatment of PTSD and
stress-related disorders,” said Eric Weisblum, Chief Executive
Officer of Silo Pharma. “The first of the two-part study was
launched in October, with the expected completion of this study
before year end 2023.
SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist that
utilizes biomarkers for the treatment of PTSD, anxiety, and other
stress-induced affective disorders. SPC-15 is being developed
as an intranasal medication. If clinically successful, SPC-15 could
qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for
drug approval. Silo Pharma is conducting preclinical studies of
SPC-15 in collaboration with Columbia University pursuant to a
sponsored research agreement and option.
About Silo Pharma
Silo Pharma Inc. is a development-stage biopharmaceutical
company focused on merging traditional therapeutics with
psychedelic research for people suffering from indications such as
PTSD, Alzheimer’s disease, and other rare neurological disorders.
Silo’s mission is to identify assets to license and fund the
research which we believe will be transformative to the well-being
of patients and the healthcare industry. For more information visit
www.silopharma.com
Forward-Looking Statements
All statements other than statements of historical fact in this
announcement are forward-looking statements that involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy, and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company's filings with the SEC.
Contact
800-705-0120 investors@silopharma.com
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Silo Pharma (NASDAQ:SILO)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024